Austrian biotech plans Zika vaccine clinical trials in 12 months

An Austrian biotech company working with the Institut Pasteur said on Tuesday it planned to start clinical trials with an experimental Zika vaccine in the next 12 months, marking a further acceleration of research in the field. Themis Bioscience has signed a licence deal with the French research institute giving it extensive rights to the Zika vaccine candidate, which is based on established measles vaccine technology.